Spyre Therapeutics (NASDAQ:SYRE) Shares Up 7.1% - Here's What Happened

Spyre Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Spyre Therapeutics shares rose 7.1% to about $100.45, while trading volume was 38% below its average.
  • Analysts’ consensus rating is “Moderate Buy,” with an average price target of $110.53; recent targets ranged from $115 to $127 among firms maintaining Buy or Outperform ratings.
  • The company’s latest quarterly loss of $0.94 per share was wider than the $0.82 analysts expected. Insiders sold 138,064 shares worth about $12.35 million over the past 90 days.
  • Interested in Spyre Therapeutics? Here are five stocks we like better.

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report)'s stock price was up 7.1% during trading on Wednesday. The stock traded as high as $100.73 and last traded at $100.4490. Approximately 697,353 shares changed hands during trading, a decline of 38% from the average daily volume of 1,123,375 shares. The stock had previously closed at $93.81.

Analyst Ratings Changes

Several brokerages recently commented on SYRE. Deutsche Bank dropped their price target on Spyre Therapeutics from $135.00 to $127.00 and set a "buy" rating for the company in a research report on Wednesday, August 26th. BTIG Research reaffirmed a "buy" rating and set a $121.00 target price on shares of Spyre Therapeutics in a research note on Monday, October 19th. Wells Fargo & Company increased their target price on shares of Spyre Therapeutics from $90.00 to $115.00 and gave the company an "overweight" rating in a research report on Wednesday, August 5th. Wedbush dropped their price target on Spyre Therapeutics from $123.00 to $120.00 and set an "outperform" rating for the company in a research report on Wednesday, November 4th. Finally, Robert W. Baird set a $120.00 target price on Spyre Therapeutics in a report on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $110.53.

Read Our Latest Stock Analysis on Spyre Therapeutics

Spyre Therapeutics Stock Up 7.3%

The stock has a market cap of $9.56 billion, a price-to-earnings ratio of -36.85 and a beta of 3.24. The company's fifty day moving average is $91.75 and its two-hundred day moving average is $76.94.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.12). Sell-side analysts predict that Spyre Therapeutics, Inc. will post -2.78 EPS for the current fiscal year.

Insider Transactions at Spyre Therapeutics

In related news, insider Heidy King-Jones sold 28,933 shares of Spyre Therapeutics stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $91.03, for a total value of $2,633,770.99. Following the sale, the insider directly owned 2,845 shares in the company, valued at $258,980.35. The trade was a 91.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $92.01, for a total transaction of $1,380,150.00. Following the sale, the chief executive officer owned 537,540 shares of the company's stock, valued at approximately $49,459,055.40. The trade was a 2.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 138,064 shares of company stock worth $12,349,518 over the last 90 days. 15.69% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SYRE. Perceptive Advisors LLC lifted its holdings in shares of Spyre Therapeutics by 23.3% during the first quarter. Perceptive Advisors LLC now owns 3,783,225 shares of the company's stock valued at $190,826,000 after purchasing an additional 714,000 shares during the last quarter. Bank of America Corp DE raised its holdings in Spyre Therapeutics by 192.6% during the 1st quarter. Bank of America Corp DE now owns 1,228,093 shares of the company's stock worth $61,945,000 after buying an additional 808,366 shares during the period. Assenagon Asset Management S.A. purchased a new stake in Spyre Therapeutics during the third quarter valued at about $53,349,000. Bellevue Group AG lifted its stake in Spyre Therapeutics by 65.2% during the third quarter. Bellevue Group AG now owns 379,870 shares of the company's stock valued at $33,820,000 after buying an additional 149,939 shares in the last quarter. Finally, ADAR1 Capital Management LLC boosted its holdings in shares of Spyre Therapeutics by 893.6% in the first quarter. ADAR1 Capital Management LLC now owns 338,323 shares of the company's stock worth $17,065,000 after buying an additional 304,272 shares during the period. Hedge funds and other institutional investors own 80.39% of the company's stock.

About Spyre Therapeutics

(Get Free Report)

Spyre Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its research focuses on therapies designed to target immune pathways involved in these conditions. The company's pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin α4β7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Spyre Therapeutics Right Now?

Before you consider Spyre Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.

While Spyre Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines